Treat-and-Extend Versus Alternate Dosing Strategies with Anti-Vascular Endothelial Growth Factor agents to treat Center Involving Diabetic Macular Edema: A Systematic Review and Meta-analysis of 2346 Eyes

Anti-vascular endothelial growth factor (Anti-VEGF) agents are the standard of care for diabetic macular edema (CI-DME) with vision loss. They are commonly administered using several treatment protocols, including fixed, pro re nata (PRN) and treat-and-extend (T&E) regimens. Because of the lack of evidence defining an ideal treatment paradigm, we systematically compared T&E with fixed or PRN regimens. Visual acuity improvement was similar when comparing T&E to fixed or PRN dosing at 12 and 24 months.

Source: Survey of Ophthalmology - April 23, 2022 Category: Opthalmology Authors: Gurkaran S. Sarohia, Keean Nanji, Mohammad Khan, Muhammad F. Khalid, Daniel Rosenberg, Deven M. Deonarain, Mark R. Phillips, Lehana Thabane, Peter Kaiser, Sunir Garg, Sobha Sivaprasad, Charles C. Wykoff, Varun Chaudhary Tags: REVI Source Type: research